Supernus Pharmaceuticals同意以8.50美元/股的价格收购Sage Therapeutics，外加一项每股价值高达3.50美元的现金形式的或有价值权利，总对价为12美元/股

2025-06-16 19:02

Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base.
Strengthens Supernus' leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform.
Expected to be significantly accretive in 2026 with potential cost synergies of up to $200 million on an annual basis.
Upfront cash payment of $8.50 per share, plus one non-tradable contingent value right (CVR) payable upon achieving certain specific milestones collectively worth up to $3.50 per share in cash, for an aggregate of up to approximately $795 million or $12.00 per share.